Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBIT Margin (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed EBIT Margin for 15 consecutive years, with 22.66% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin rose 605.0% to 22.66% in Q3 2025 year-over-year; TTM through Sep 2025 was 9.31%, a 8180.0% increase, with the full-year FY2024 number at 15.28%, up 7454.0% from a year prior.
  • EBIT Margin was 22.66% for Q3 2025 at Gyre Therapeutics, up from 0.47% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 83.54% in Q3 2023 to a low of 1851.51% in Q1 2022.
  • A 5-year average of 425.79% and a median of 2.39% in 2024 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: crashed -149855bps in 2021, then soared 187824bps in 2023.
  • Gyre Therapeutics' EBIT Margin stood at 845.67% in 2021, then surged by 95bps to 39.68% in 2022, then plummeted by -751bps to 337.53% in 2023, then skyrocketed by 101bps to 2.39% in 2024, then surged by 850bps to 22.66% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EBIT Margin are 22.66% (Q3 2025), 0.47% (Q2 2025), and 10.3% (Q1 2025).